Pharmacokinetic Nanoparticles – VHIR Annual Report 2024

Publications

100.00

%Q1

Number of citations

50.00

% Open Access Publications

Ongoing Projects

Number of Presented Theses

Number of Active Clinical Trials

In 2024 we presented our results in the study of the interactions of extremely small biocompatible NPs and the structure of SAR-COV-2 spikes, how nanoparticles insert a three dimensional cavity structure of proteins for function inhibition: The Case of CeO2 and SARS-CoV-2 while continuing studying the effects of cerium oxide nanoparticles CeO2 NPs on reactive oxygen species and mitochondria and from there to metabolism and inflammation. Regarding SARS-Cov-2, we successfully immunised mice with virus-like particles made of a 50 nm Au NP decorated with a mosaic of spike proteins. We have also been studying the potential hazardous effects of nanomaterials, always promoting their safe and sustainable introduction into society. On this line, we also continued our work on the interactions of proteins and nanoparticles related to the concept of protein corona formation. An in-house developed methodology for analyzing NPs inside the cell under confocal microscopy has also been presented.

eCORE

Advanced Therapies and Advanced Interventions, Nanomedicine, Transplant & Donation
Personalized Medicine, Innovative Diagnostics, Molecular Imaging & Digital Health

Team

Group Leader
Victor Franco Puntes

Researchers
Vivian Salazar, Joan Comenge i Farreras

PhD Students
Lena Montaña Ernst, Ramon Gonzalez Rioja, Joana Ramins Garcia

Selected Publications

Casals E, Vitali M & Puntes V
The nanoparticle-Protein Corona untold history (1907–2007)
nanotoday
DOI: 10.1016/j.nantod.2024.102435
IF: 13.50

Gusta MF, Ernst LM, Moriones OH, Piella J, Valeri M, Bastus NG, Puntes V
Long-Term Intracellular Tracking of Label-Free Nanoparticles in Live Cells and Tissues with Confocal Microscopy.
Small Methods. 2024 Oct;8(10):e2301713.
DOI: 10.1002/smtd.202301713
IF: 10.70

Salazar VA, Comenge J, Suarez-Lopez R, Burger JA, Sanders RW, Bastus NG, Jaime C, Joseph-Munne J, Puntes V
Gold Nanoparticle Virus-like Particles Presenting SARS-CoV-2 Spike Protein: Synthesis, Biophysical Properties and Immunogenicity in BALB/c Mice.
Vaccines (Basel). 2024 Jul 23;12(8):829.
DOI: 10.3390/vaccines12080829.
IF: 5.20

Longhin EM, Rios-Mondragon I, Mariussen E, Zheng C, Busquets M, Gajewicz-Skretna A, Hofshagen OB, Bastus NG, Puntes VF, Cimpan MR, Shaposhnikov S, Dusinska M, Runden-Pran E
Hazard assessment of nanomaterials: how to meet the requirements for (next generation) risk assessment.
Part Fibre Toxicol. 2024 Dec 27;21(1):54.
DOI: 10.1186/s12989-024-00615-4.
IF: 7.20

Guofang Zhang, Xiaofeng Wang, Guocheng Wang, Xiaoman Suo, Yu Qiu, Rong-Hua Luo, Yingnan Liu, Qi Li, Wenhe Luo, Zhenzhen Shi, Fangfang Liu, Zhongda Li, Jing Qu, Liang Li, Neus G Bastús, Martin Himly, Liming Wang, Feng-Liang Liu, Yong-Tang Zheng, Victor Puntes, Yang Li
Nanoparticles insert a three dimensional cavity structure of proteins for function inhibition: The Case of CeO2 and SARS-CoV-2
Nanotoday. 2024 Oct 1;58
DOI: 10.1016/j.nantod.2024.102183
IF: 13.50

Selected Projects

Next generation serology: Immune profiling via graphene-enhanced DNA scaffold sensors (SerDNA
Principal Investigator: Victor Puntes
Agency: AEI
Funding: 45,000 €
Period: 2024-2028

2-in-1 Nanogold for a Synergistic Enhancement of Radiotherapy and Chemotherapy
Principal Investigator: Victor Puntes
Agency: AECC
Funding: 205,000 €
Period: 2024-2027

Improving Brain Arteriovenous Malformation Cure with local Antioncogenic Nanoparticle Embolization
Principal Investigator: Victor Puntes
Agency: LaCaixaHealth
Funding: 200,000 €
Period: 2024-2027

CeO2 Nanoparticles for Metabolic Regulation and Treatment of Oxidative stress and Disease. (TRANSCERIA-BIO)
Principal Investigator: Victor Puntes
Agency: MINECO
Funding: 312,700 €
Period: 2024-2028

Commercialization of Luceria, a nanotechnology-based solution for the eye
Principal Investigator: Victor Puntes
Agency: VHIR
Funding: 15,000 €
Period: 2024-2025